Fraction of samples with ASNase activity above 0.1 IU/mL
| Antibody ratio . | Induction . | DI no. 1 . | DI no. 2 . |
|---|---|---|---|
| Native ASNase | |||
| Below 1.5 | 79/89 (89%) | 54/58 (93%) | 55/59 (93%) |
| 1.5-2.0 | 3/3 (100%) | 4/8 (50%) | 6/7 (86%) |
| Above 2.0 | 5/8 (63%) | 10/20 (50%) | 7/11 (64%) |
| Pegaspargase | |||
| Below 1.5 | 95/98 (97%) | 67/69 (97%) | 63/65 (95%) |
| 1.5-2.0 | 0/0 | 5/5 (100%) | 5/5 (100%) |
| Above 2.0 | 3/3 (100%) | 2/2 (100%) | 9/9 (100%) |
| Antibody ratio . | Induction . | DI no. 1 . | DI no. 2 . |
|---|---|---|---|
| Native ASNase | |||
| Below 1.5 | 79/89 (89%) | 54/58 (93%) | 55/59 (93%) |
| 1.5-2.0 | 3/3 (100%) | 4/8 (50%) | 6/7 (86%) |
| Above 2.0 | 5/8 (63%) | 10/20 (50%) | 7/11 (64%) |
| Pegaspargase | |||
| Below 1.5 | 95/98 (97%) | 67/69 (97%) | 63/65 (95%) |
| 1.5-2.0 | 0/0 | 5/5 (100%) | 5/5 (100%) |
| Above 2.0 | 3/3 (100%) | 2/2 (100%) | 9/9 (100%) |
Native ASNase serum samples obtained days 3-14 after the first native ASNase treatment. Pegaspargase serum samples obtained days 3-14 after the first native ASNase treatment. DI indicates delayed intensification.